Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. PXDX-101 has been well tolerated in patients with advanced solid tumors. PXDX-101 is currently in clinical trials, and is being developed by Ignyta.
LPI (LP Information)' newest research report, the “Entrectinib Industry Forecast” looks at past sales and reviews total world Entrectinib sales in 2022, providing a comprehensive analysis by region and market sector of projected Entrectinib sales for 2023 through 2029. With Entrectinib sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Entrectinib industry.
This Insight Report provides a comprehensive analysis of the global Entrectinib landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Entrectinib portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Entrectinib market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Entrectinib and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Entrectinib.
The global Entrectinib market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Entrectinib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Entrectinib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Entrectinib is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Entrectinib players cover BOCSCI, APExBIO Technology, Cayman Chemical, ChemScence, Crysdot, Medical Isotopes, TargetMol Chemicals, Toronto Research Chemicals and Beijing Jingming Biotechnology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Entrectinib market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
0.99
0.98
Segmentation by application
Anaplastic Lymphoma
C-ros Oncogene
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BOCSCI
APExBIO Technology
Cayman Chemical
ChemScence
Crysdot
Medical Isotopes
TargetMol Chemicals
Toronto Research Chemicals
Beijing Jingming Biotechnology
Cool Pharm
Shanghai Lollane Biological Technology
Shanghai Macklin Biochemical
Shanghai Muse Health Tech
ATK Chemical
Shanghai Send Pharmaceutical Technology
Shanghai Yuanye Bio-Technology
Wuhan Sun-Shine Bio-Technology
Key Questions Addressed in this Report
What is the 10-year outlook for the global Entrectinib market?
What factors are driving Entrectinib market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Entrectinib market opportunities vary by end market size?
How does Entrectinib break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Entrectinib Annual Sales 2018-2029 2.1.2 World Current & Future Analysis for Entrectinib by Geographic Region, 2018, 2022 & 2029 2.1.3 World Current & Future Analysis for Entrectinib by Country/Region, 2018, 2022 & 2029 2.2 Entrectinib Segment by Type 2.2.1 0.99 2.2.2 0.98 2.3 Entrectinib Sales by Type 2.3.1 Global Entrectinib Sales Market Share by Type (2018-2023) 2.3.2 Global Entrectinib Revenue and Market Share by Type (2018-2023) 2.3.3 Global Entrectinib Sale Price by Type (2018-2023) 2.4 Entrectinib Segment by Application 2.4.1 Anaplastic Lymphoma 2.4.2 C-ros Oncogene 2.5 Entrectinib Sales by Application 2.5.1 Global Entrectinib Sale Market Share by Application (2018-2023) 2.5.2 Global Entrectinib Revenue and Market Share by Application (2018-2023) 2.5.3 Global Entrectinib Sale Price by Application (2018-2023) 3 Global Entrectinib by Company 3.1 Global Entrectinib Breakdown Data by Company 3.1.1 Global Entrectinib Annual Sales by Company (2018-2023) 3.1.2 Global Entrectinib Sales Market Share by Company (2018-2023) 3.2 Global Entrectinib Annual Revenue by Company (2018-2023) 3.2.1 Global Entrectinib Revenue by Company (2018-2023) 3.2.2 Global Entrectinib Revenue Market Share by Company (2018-2023) 3.3 Global Entrectinib Sale Price by Company 3.4 Key Manufacturers Entrectinib Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Entrectinib Product Location Distribution 3.4.2 Players Entrectinib Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Entrectinib by Geographic Region 4.1 World Historic Entrectinib Market Size by Geographic Region (2018-2023) 4.1.1 Global Entrectinib Annual Sales by Geographic Region (2018-2023) 4.1.2 Global Entrectinib Annual Revenue by Geographic Region (2018-2023) 4.2 World Historic Entrectinib Market Size by Country/Region (2018-2023) 4.2.1 Global Entrectinib Annual Sales by Country/Region (2018-2023) 4.2.2 Global Entrectinib Annual Revenue by Country/Region (2018-2023) 4.3 Americas Entrectinib Sales Growth 4.4 APAC Entrectinib Sales Growth 4.5 Europe Entrectinib Sales Growth 4.6 Middle East & Africa Entrectinib Sales Growth 5 Americas 5.1 Americas Entrectinib Sales by Country 5.1.1 Americas Entrectinib Sales by Country (2018-2023) 5.1.2 Americas Entrectinib Revenue by Country (2018-2023) 5.2 Americas Entrectinib Sales by Type 5.3 Americas Entrectinib Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Entrectinib Sales by Region 6.1.1 APAC Entrectinib Sales by Region (2018-2023) 6.1.2 APAC Entrectinib Revenue by Region (2018-2023) 6.2 APAC Entrectinib Sales by Type 6.3 APAC Entrectinib Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Entrectinib by Country 7.1.1 Europe Entrectinib Sales by Country (2018-2023) 7.1.2 Europe Entrectinib Revenue by Country (2018-2023) 7.2 Europe Entrectinib Sales by Type 7.3 Europe Entrectinib Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Entrectinib by Country 8.1.1 Middle East & Africa Entrectinib Sales by Country (2018-2023) 8.1.2 Middle East & Africa Entrectinib Revenue by Country (2018-2023) 8.2 Middle East & Africa Entrectinib Sales by Type 8.3 Middle East & Africa Entrectinib Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Entrectinib 10.3 Manufacturing Process Analysis of Entrectinib 10.4 Industry Chain Structure of Entrectinib 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Entrectinib Distributors 11.3 Entrectinib Customer 12 World Forecast Review for Entrectinib by Geographic Region 12.1 Global Entrectinib Market Size Forecast by Region 12.1.1 Global Entrectinib Forecast by Region (2024-2029) 12.1.2 Global Entrectinib Annual Revenue Forecast by Region (2024-2029) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Entrectinib Forecast by Type 12.7 Global Entrectinib Forecast by Application 13 Key Players Analysis 13.1 BOCSCI 13.1.1 BOCSCI Company Information 13.1.2 BOCSCI Entrectinib Product Portfolios and Specifications 13.1.3 BOCSCI Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.1.4 BOCSCI Main Business Overview 13.1.5 BOCSCI Latest Developments 13.2 APExBIO Technology 13.2.1 APExBIO Technology Company Information 13.2.2 APExBIO Technology Entrectinib Product Portfolios and Specifications 13.2.3 APExBIO Technology Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.2.4 APExBIO Technology Main Business Overview 13.2.5 APExBIO Technology Latest Developments 13.3 Cayman Chemical 13.3.1 Cayman Chemical Company Information 13.3.2 Cayman Chemical Entrectinib Product Portfolios and Specifications 13.3.3 Cayman Chemical Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.3.4 Cayman Chemical Main Business Overview 13.3.5 Cayman Chemical Latest Developments 13.4 ChemScence 13.4.1 ChemScence Company Information 13.4.2 ChemScence Entrectinib Product Portfolios and Specifications 13.4.3 ChemScence Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.4.4 ChemScence Main Business Overview 13.4.5 ChemScence Latest Developments 13.5 Crysdot 13.5.1 Crysdot Company Information 13.5.2 Crysdot Entrectinib Product Portfolios and Specifications 13.5.3 Crysdot Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.5.4 Crysdot Main Business Overview 13.5.5 Crysdot Latest Developments 13.6 Medical Isotopes 13.6.1 Medical Isotopes Company Information 13.6.2 Medical Isotopes Entrectinib Product Portfolios and Specifications 13.6.3 Medical Isotopes Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.6.4 Medical Isotopes Main Business Overview 13.6.5 Medical Isotopes Latest Developments 13.7 TargetMol Chemicals 13.7.1 TargetMol Chemicals Company Information 13.7.2 TargetMol Chemicals Entrectinib Product Portfolios and Specifications 13.7.3 TargetMol Chemicals Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.7.4 TargetMol Chemicals Main Business Overview 13.7.5 TargetMol Chemicals Latest Developments 13.8 Toronto Research Chemicals 13.8.1 Toronto Research Chemicals Company Information 13.8.2 Toronto Research Chemicals Entrectinib Product Portfolios and Specifications 13.8.3 Toronto Research Chemicals Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.8.4 Toronto Research Chemicals Main Business Overview 13.8.5 Toronto Research Chemicals Latest Developments 13.9 Beijing Jingming Biotechnology 13.9.1 Beijing Jingming Biotechnology Company Information 13.9.2 Beijing Jingming Biotechnology Entrectinib Product Portfolios and Specifications 13.9.3 Beijing Jingming Biotechnology Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.9.4 Beijing Jingming Biotechnology Main Business Overview 13.9.5 Beijing Jingming Biotechnology Latest Developments 13.10 Cool Pharm 13.10.1 Cool Pharm Company Information 13.10.2 Cool Pharm Entrectinib Product Portfolios and Specifications 13.10.3 Cool Pharm Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.10.4 Cool Pharm Main Business Overview 13.10.5 Cool Pharm Latest Developments 13.11 Shanghai Lollane Biological Technology 13.11.1 Shanghai Lollane Biological Technology Company Information 13.11.2 Shanghai Lollane Biological Technology Entrectinib Product Portfolios and Specifications 13.11.3 Shanghai Lollane Biological Technology Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.11.4 Shanghai Lollane Biological Technology Main Business Overview 13.11.5 Shanghai Lollane Biological Technology Latest Developments 13.12 Shanghai Macklin Biochemical 13.12.1 Shanghai Macklin Biochemical Company Information 13.12.2 Shanghai Macklin Biochemical Entrectinib Product Portfolios and Specifications 13.12.3 Shanghai Macklin Biochemical Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.12.4 Shanghai Macklin Biochemical Main Business Overview 13.12.5 Shanghai Macklin Biochemical Latest Developments 13.13 Shanghai Muse Health Tech 13.13.1 Shanghai Muse Health Tech Company Information 13.13.2 Shanghai Muse Health Tech Entrectinib Product Portfolios and Specifications 13.13.3 Shanghai Muse Health Tech Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.13.4 Shanghai Muse Health Tech Main Business Overview 13.13.5 Shanghai Muse Health Tech Latest Developments 13.14 ATK Chemical 13.14.1 ATK Chemical Company Information 13.14.2 ATK Chemical Entrectinib Product Portfolios and Specifications 13.14.3 ATK Chemical Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.14.4 ATK Chemical Main Business Overview 13.14.5 ATK Chemical Latest Developments 13.15 Shanghai Send Pharmaceutical Technology 13.15.1 Shanghai Send Pharmaceutical Technology Company Information 13.15.2 Shanghai Send Pharmaceutical Technology Entrectinib Product Portfolios and Specifications 13.15.3 Shanghai Send Pharmaceutical Technology Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.15.4 Shanghai Send Pharmaceutical Technology Main Business Overview 13.15.5 Shanghai Send Pharmaceutical Technology Latest Developments 13.16 Shanghai Yuanye Bio-Technology 13.16.1 Shanghai Yuanye Bio-Technology Company Information 13.16.2 Shanghai Yuanye Bio-Technology Entrectinib Product Portfolios and Specifications 13.16.3 Shanghai Yuanye Bio-Technology Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.16.4 Shanghai Yuanye Bio-Technology Main Business Overview 13.16.5 Shanghai Yuanye Bio-Technology Latest Developments 13.17 Wuhan Sun-Shine Bio-Technology 13.17.1 Wuhan Sun-Shine Bio-Technology Company Information 13.17.2 Wuhan Sun-Shine Bio-Technology Entrectinib Product Portfolios and Specifications 13.17.3 Wuhan Sun-Shine Bio-Technology Entrectinib Sales, Revenue, Price and Gross Margin (2018-2023) 13.17.4 Wuhan Sun-Shine Bio-Technology Main Business Overview 13.17.5 Wuhan Sun-Shine Bio-Technology Latest Developments 14 Research Findings and Conclusion